证券代码：002737 证券简称：葵花药业 葵花药业集团股份有限公司投资者关系活动记录表 | --- | --- | |------------------------|----------------------------------------------------------------------| | | | | | | | 投资者关系活动类别 | | | | | | | | | | | | | | | | | | | | | | | | | 人保资产管理有限公司、长青、亚太财产保险有限公司、健顺投资、淡水泉、 | | | 湘财基金管理有限公司（上海）、浙商证券资产管理有限公司、东方自营、惠 | | 活动参与人员 | 升基金管理有限公司、淳厚基金管理有限公司、中国人民养老保险有限责任公 | | | 司、长城基金管理有限公司、国寿安保基金管理有限公司、东方红资产管理公 | | | 司、财通证券资产管理有限公司、上海石锋资产管理有限公司、博道基金管理 | | | 有限公司、富国基金管理有限公司、正心谷、前海开源基金管理有限公司、景 | | | 顺长城基金管理有限公司、重庆市金科投资控股（集团）有限责 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥3,033,922,653.76, representing a year-on-year increase of 34.89%[24] - In the first half of 2023, the company's total revenue reached ¥3,033,922,653.76, representing a year-on-year increase of 34.89% compared to ¥2,249,168,302.98 in the same period last year[47] - The pharmaceutical sector contributed ¥3,025,746,701.07, accounting for 99.73% of total revenue, with a growth of 35.00% from ¥2,241,305,953.81 in the previous year[47] - The traditional Chinese medicine segment generated ¥2,172,043,256.24, making up 71.59% of total revenue, with a year-on-year increase of 34.25%[47] - Net profit attributable to shareholders was ¥638,159,703.16, a 59.06% increase from ¥401,217,652.72 year-on-year[177] - The net profit after deducting non-recurring gains and losses was ¥584,336,899.40, up 63.38% from ¥357,652,282.42 in the previous year[177] - Basic earnings per share increased to ¥1.10, a 59.42% rise compared to ¥0.69 in the same period last year[177] - The gross profit margin for the pharmaceutical sector was 59.54%, which is an increase of 0.49% year-on-year[193] - The revenue from traditional Chinese medicine products was approximately CNY 2.17 billion, with a gross profit margin of 59.91%[193] - The company reported a significant increase in sales for its chemical drugs, with revenue of approximately CNY 755 million and a gross profit margin of 60.87%[193] Operating Costs and Expenses - Operating costs amounted to ¥1,239,815,365.67, reflecting a year-on-year increase of 34.56% due to higher sales volume[24] - Sales expenses were reported at ¥719,950,300.24, which is a 35.47% increase compared to the previous year[24] - The net cash flow from operating activities decreased by 23.68% to ¥375,777,964.73, primarily due to increased cash payments for goods and services[24] - The net cash flow from financing activities showed a decline of 175.45%, resulting in a net outflow of ¥997,505,746.01 due to increased repayments of loans and dividend distributions[24] - The total expense recognized for equity-settled share-based payments in the first half of 2023 amounted to ¥10,456,999.48[111] Research and Development - The company invested ¥47,228,443.45 in research and development, marking a 1.32% increase year-on-year[24] - The company is actively developing 80 health product projects, including research on probiotics and has obtained 4 invention patents during the reporting period[23] - The company has focused on "self-research + external expansion" to enhance its product pipeline in pediatrics, adult digestion, and gynecology, achieving significant progress in product registrations and trials[45] - The company is focusing on developing key product categories, particularly chronic disease medications, women's health products, and probiotic health products[38] Strategic Focus and Market Position - The company focuses on the pediatric medication sector as its primary core strategy, emphasizing the development of specialized medications for children, the elderly, and women's health[42] - The company plans to continue its long-term commitment to the premium medication sector, focusing on core products and maintaining a leading position in niche markets[42] - The company aims to enhance brand recognition and engagement through targeted marketing strategies, including precise advertising and interactive communication methods[41] - The company continues to focus on children's medication as its core strategy, with the "Little Sunflower" brand gaining competitive advantages in the industry[182] - The company is actively pursuing market expansion and product development strategies to strengthen its competitive position in the industry[190] Environmental and Social Responsibility - The company reported a wastewater treatment capacity of 600 tons per day at its Jizhou facility, with a pollution discharge intensity of 500 tons per day[95] - The company achieved a wastewater treatment capacity of 350 tons per day at its Hengshui facility, with a discharge intensity of 0 to 200 tons per day[95] - The company’s wastewater treatment facility in Tangshan has a capacity of 5000 cubic meters per hour, achieving a treatment efficiency of 90%[95] - The company donated cash and medicines worth nearly 2.6 million yuan to local charitable organizations during the reporting period[100] - The company has established emergency response plans for environmental incidents in compliance with relevant laws and regulations[118] - The company adheres to strict monitoring standards for pollutants, including COD ≤ 500 mg/L and ammonia ≤ 35 mg/L[120] - The company has committed to conducting regular environmental monitoring, including quarterly checks for total phosphorus and total nitrogen[120] - The company has implemented measures to ensure compliance with air quality standards, including limits on sulfur dioxide and hydrogen sulfide emissions[120] Organizational Management and Development - The company is actively enhancing its organizational management and talent development to support its strategic goals and improve operational efficiency[68] - The company aims to enhance its management capabilities to mitigate potential management risks associated with its expanding business scale[104] - The company has established a brand operation model that separates children's medications from adult premium medications, enhancing organizational efficiency[42] Regulatory and Compliance - The company is facing increased regulatory pressures in the pharmaceutical industry, which may impact operational performance[81] - There were no violations or penalties reported that could impact the company's operations[122] - The company has no significant litigation or arbitration matters during the reporting period[136] - The company is classified as a key pollutant discharge unit by environmental protection authorities[142] Cash Flow and Investments - The net cash flow from investing activities increased significantly by 156.78% to ¥194,216,947.59, attributed to a decrease in cash payments for investment activities[24] - Cash and cash equivalents at the end of the reporting period amounted to ¥1,971,462,478.76, representing 30.29% of total assets, a decrease of 3.82% from the previous year[72] - The company made a total investment of ¥4,000,000.00 during the reporting period, a substantial decrease of 93.33% from ¥60,000,000.00 in the same period last year[74] - Investment income for the period was ¥24,698,446.29, accounting for 3.03% of total profit, primarily from bank wealth management products[71] Awards and Recognition - The company has been recognized in the "2022 Annual Top 100 Chinese Pharmaceutical Industry - Brand List" at the 2023 Misi Conference[40] - The company received several awards in 2023, including the "West Lake Award - Most Popular Star Product" at the Wuzhen Health Conference[185]

葵花药业集团股份有限公司 独立董事关于控股股东及其他关联方占用公司资金、 公司对外担保情况的专项说明和独立意见 根据《中华人民共和国公司法》、《上市公司独立董事规则》、 《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律 监管指引第 1 号—主板上市公司规范运作》、《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》、《深圳证券交 易所上市公司自律监管指南第 1 号——业务办理》以及《公司章程》 等有关规定，作为葵花药业集团股份有限公司（以下简称"公司"） 的独立董事，现就公司对外担保及关联方资金占用情况发表独立意见 如下： 1、报告期内,公司严格遵守相关法律、法规、规范性文件及《公 司章程》的有关规定，公司未发生控股股东及其他关联方非经营性占 用公司资金情况，也不存在以前期间发生并延续到报告期的控股股东 及其他关联方非经营性占用公司资金的情况。 独立董事：林瑞超、崔丽晶、施先旺 2023 年 8 月 24 日 2、报告期内，公司严格执行中国证监会《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》等相关规定，不存 在对合并财务报表范围外的公司提供担保的情形；不存 ...

汇总表第 1 页 单位：万元 | | | | | 2023 年期初 | 2023 年半年 度占用累计 | 年半年 2023 | 2023 年半年 | 2023 年半年度 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占 | 资金占用方名称 | 占用方与上市公 | 上市公司核算的会计科 | 占用资金余 | 发生金额 | 度占用资金 | 度度偿还累 | 期末占用资金 | 占用形成原因 | 占用性质 | | 用 | | 司的关联关系 | 目 | | | 的利息(如 | | | | | | | | | | 额 | （不含利 | 有) | 计发生金额 | 余额 | | | | | | | | | 息） | | | | | | | 控股股东、实际控 | | | | | | | | | | | | 制人及其附属企 | | | | | | | | | | 非经营性占用 | | 业 | | | | | | | | | | | | 小计 | - | - | - | | | | | | - | - | | 前控股股 ...

证券代码：002737 证券简称：葵花药业 公告编号：2023-033 葵花药业集团股份有限公司 第四届监事会第十九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）第四届监事 会第十九次会议于 2023 年 8 月 24 日以通讯方式召开。本次会议由公司监事会主 席兰芬女士召集，会议通知及议案于 2023 年 8 月 14 日通过电子邮件形式发出。 会议应参加表决监事三人，实际参加表决监事三人，本次会议召集和召开程 序符合《公司法》及《公司章程》之规定，会议决议合法有效。 二、监事会会议审议情况 1、审议通过《关于公司 2023 年半年度报告全文及摘要的议案》 经审核，监事会认为，公司董事会编制和审议公司 2023 年半年度报告全文 及摘要的程序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、 完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大 遗漏。 1 资金往来，不存在控股股东及其他关联方非经营性占用公司资金之情形；不存在 为控股股 ...

葵花药业集团股份有限公司 第四届董事会第二十六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 葵花药业集团股份有限公司（以下简称"公司"或"本公司"）第四届董事 会第二十六次会议于 2023 年 8 月 24 日上午 9 时 30 分以通讯方式召开。会议由 公司董事长关玉秀女士召集，会议通知及议案于 2023 年 8 月 14 日通过电子邮件 形式发出。会议应参加表决董事 9 人，实际参加表决董事 9 人。 证券代码：002737 证券简称：葵花药业 公告编号：2023-032 公司独立董事对本议案发表了独立意见。 《独立董事意见》、《公司 2023 年半年度非经营性资金占用及其他关联资 金 往 来 情 况 汇 总 表 》 披 露 于 本 公 司 指 定 信 息 披 露 媒 体 巨 潮 资 讯 网 （www.cninfo.com.cn ）。 表决结果：同意 9 票，反对 0 票，弃权 0 票，通过。 三、备查文件： 本次会议召集、召开程序符合《公司法》及相关法律法规以及《公司章程》 之规定，会议决议合法有效。 二、董事会 ...

2 | | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访  业绩说明会 | | 投资者关系活动类别 | 新闻发布会 □路演活动 | | | 现场参观 | | | 其他 | | 参与单位名称及人员姓名 | 投资者网上提问 | | 时间 | 2023 年 5 月 15 日 (周一) 下午 14:00-16:30 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用网 | | | 络远程的方式召开业绩说明会 | | 上市公司接待人员姓名 | 1、财务负责人吴春红女士 | | | 2、董事会秘书周广阔先生 | | 形式 | 文字交流 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、请问二季度以来公司的经营情况如何？ | | | 答：您好，自 23 年年初以来公司经营情况良好，业绩指标符合预期。感谢 | | | 关注！ | | | 2、为什么每年第三季度的业绩特别差呢？ | | | 答：您好，公司部分品类的产品存在季节性特点。谢谢。 | | | 3、实控人目 ...

证券代码：002737 证券简称：葵花药业 公告编号：2023-021 葵花药业集团股份有限公司 关于参加黑龙江辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，葵花药业集团股份有限公司(以下简称 "公司")将参加由黑龙江证监局、黑龙江省上市公司协会与深圳市全景网络有 限公司联合举办的"2023 年黑龙江辖区上市公司投资者集体接待日活动"，现 将相关事项公告如下: 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 (http://rs.p5w.net)；或关注微信公众号(名称:全景财经)；或下载全景路演 APP,参与本次互动交流。活动时间为 2023 年 5 月 15 日(周一) 14:00-16:30。届 时公司董事会秘书周广阔先生、公司财务负责人吴春红女士将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计划、股权激励和可持续发展 等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与! 特此公告。 葵花药业集团股份有限公司 ...

1 | 3、业绩能保持多久，谢谢？ | | --- | | 答：公司未来将坚持既定战略，充分发挥公司品牌影响力大、品种种类丰 | | 富、以及团队战斗力强的优势，持续保持公司的市场竞争力。 | | 4、二季度业绩能继续保持高增长？ | | 答：公司将按照既定战略落地经营计划，谢谢！ | | 5、请问，葵花会不会大举进军保健品行业？ | | 答：大健康产业是公司药品业务的重要补充和未来的重要增长点之一。 | | 6、（1）公司老董事长从 2019 年至今一直在连续减持本公司股票是出于什 | | 么原因？（2）公司留存的大量现金未来还会继续进行现金理财吗？是否考 | | 虑股票基金等产品的投资？是否考虑提高分红比例？（3）管理层认为公司 | | 自身能够保持连续增长的原因是什么？未来会如何继续扩张？ | | 答：1、公司老董事长减持股份主要原因为个人资金需求；2、公司会在综 | | 合考虑安全性和收益性基础上对公司的现金进行管理，公司将在稳健经营 | | 的基础上尽可能保持分红政策的稳定性和连续性；3、公司未来将坚持既定 | | 战略，充分发挥公司品牌影响力大、品种储备丰富以及团队战斗力强的优 | | 势，持续保 ...

Revenue and Profit - The company's revenue for Q1 2023 was CNY 1,765,521,894.46, representing a 47.31% increase compared to CNY 1,198,471,522.45 in the same period last year[14]. - Net profit attributable to shareholders was CNY 406,135,072.45, an increase of 85.30% from CNY 219,172,003.91 year-over-year[14]. - The net profit after deducting non-recurring gains and losses was CNY 390,404,960.30, reflecting a 92.25% increase compared to CNY 203,076,117.89 in the previous year[14]. - The net profit for the first quarter was CNY 435,364,881.11, representing an increase from CNY 234,304,233.39 in the previous year, which is a growth of approximately 86%[38]. - The total revenue for the quarter was CNY 514,911,099.53, compared to CNY 286,565,292.81 in the same period last year, indicating a year-over-year increase of about 79.5%[38]. - Basic earnings per share increased to CNY 0.70, up 84.21% from CNY 0.38 in the previous year[14]. - The basic and diluted earnings per share were both CNY 0.70, up from CNY 0.38 in the previous year, reflecting an increase of 84.2%[38]. Cash Flow and Assets - The company's cash flow from operating activities was CNY 249,028,652.64, down 42.17% from CNY 430,597,673.80 in the same period last year[14]. - Net cash flow from operating activities decreased by 42.2% to ¥249,028,652.64, down from ¥430,597,673.80, mainly due to increased cash payments for goods and services[29]. - Cash inflow from investment activities was $252,569,927.27, compared to $355,539,307.25 in the previous period, reflecting a decrease of 29.0%[50]. - Cash outflow for operating activities totaled $1,464,236,440.00, which is a 38.6% increase from $1,055,974,047.54 in the previous period[50]. - The company's total assets amounted to ¥7,111,948,904.92, compared to ¥7,031,765,675.45 in the same period last year[37]. - The total assets of the company reached CNY 7,111,948,904.92, compared to CNY 7,031,765,675.45 at the end of the previous year, showing a slight increase of approximately 1.1%[46]. - Cash and cash equivalents at the end of the period were CNY 2,850,259,526.27, up from CNY 1,758,239,735.95, marking an increase of about 62.1%[40]. Liabilities and Equity - Total assets at the end of the reporting period were CNY 7,111,948,904.92, a 1.14% increase from CNY 7,031,765,675.45 at the end of the previous year[14]. - Shareholders' equity attributable to the parent company increased by 9.84% to CNY 4,618,437,870.45 from CNY 4,204,751,036.78[14]. - The total liabilities amounted to CNY 2,230,315,881.43, down from CNY 2,593,018,932.11, indicating a decrease of approximately 13.9%[46]. - The company’s equity attributable to shareholders was CNY 584,000,000.00, unchanged from the previous year[46]. Expenses and Financial Performance - Operating costs rose to ¥714,027,194.57, reflecting a 46.3% increase from ¥487,891,887.11 in the previous year, driven by sales growth[29]. - R&D expenses increased by 47.6% to ¥21,168,133.51, up from ¥14,338,611.92, attributed to the progress of R&D projects[29]. - The company’s net profit for the period increased, leading to a 51.4% rise in income tax expenses to ¥79,415,781.39 from ¥52,465,396.81[29]. - Financial expenses showed a negative value of -¥5,565,071.31, reflecting a 114.3% increase in interest income compared to the previous year[29]. Other Developments - The company did not report any new product developments or market expansion strategies during this quarter[20]. - The company decided to deregister its wholly-owned subsidiary, Harbin New Kui Pharmaceutical Technology Co., Ltd., during the reporting period[44]. - The company reported a significant decrease in contract liabilities by 74.20%, from ¥551,542,218.53 to ¥142,315,162.92, due to revenue recognition based on performance progress[29].